@Article{duepublico_mods_00078453,
  author = 	{Tfelt-Hansen, Peer
		and Diener, Hans-Christoph},
  title = 	{Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks},
  year = 	{2020},
  month = 	{Jul},
  day = 	{13},
  keywords = 	{controlled trials; headache relief; Migraine attack; pain freedom; treatment},
  abstract = 	{Background: Pain freedom after 2 hours is the recommended primary endpoint by the International Headache Society in randomized trials investigating drug treatment of acute migraine attacks. In order to demonstrate an early effect of a drug, some drug companies, however, have promoted headache relief (improvement from severe or moderate pain to mild or no pain) at earlier time points than 2 hours as outcome parameter. Methods and results: We analyzed the relationship between pain freedom and headache relief in acute migraine trials and observed that persistent mild headache constituted 90{\%} of headache relief after 0.5 hour and 40{\%} of headache relief after 2 hours. Conclusion: Headache relief at 2 hours should in our view only be used as an outcome measure for comparison with historic data. Prior to 2 hours, headache relief varies with time from intake and the therapeutic gain is very small. Therefore, pain freedom should be used at these early time points.},
  note = 	{<p>Tfelt-Hansen P, Diener H-C. Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks. <em>Cephalalgia</em>. 2020;40(12):1331-1335. doi:<a href="https://doi.org/10.1177/0333102420941827">10.1177/0333102420941827</a></p>

<p>First published online July 13, 2020</p>},
  note = 	{Version of Record / Verlagsversion},
  note = 	{Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-gef{\"o}rderten) Allianz- bzw. Nationallizenz frei zug{\"a}nglich.
<hr />This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.},
  note = 	{<p>OA Agreement: Deutsches Nationalkonsortium: Sage Journals Online Publish {\&}amp;{\&}{\#}xa0; Read. Zweitver{\"o}ffentlichung Version "Verlags-PDF" durch "Autor und Institution" erlaubt. Embargofrist: 12 Monate.</p>

<p>OA-Rechte lt. EZB: https://ezb.ur.de/api/oa{\_}rights?bibid=UGHE{\&}amp;issn=0333-1024{\&}amp;year=2020{\&}amp;format=application/json</p>

<p>Stand der Information 26.05.2023</p>},
  doi = 	{10.1177/0333102420941827},
  url = 	{https://duepublico2.uni-due.de/receive/duepublico_mods_00078453},
  url = 	{https://doi.org/10.1177/0333102420941827},
  file = 	{:https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00078064/Cephalalgia_2020_40_1331-1335.pdf:PDF},
  language = 	{en}
}